Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Polyarticular Juvenile Idiopathic Arthritis Drug Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Status and Forecast (2016-2027)
      • 1.3.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Supply by Company

    • 2.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume by Company
    • 2.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Value by Company
    • 2.3 Global Polyarticular Juvenile Idiopathic Arthritis Drug Price by Company
    • 2.4 Polyarticular Juvenile Idiopathic Arthritis Drug Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Polyarticular Juvenile Idiopathic Arthritis Drug Market Status by Category

    • 3.1 Polyarticular Juvenile Idiopathic Arthritis Drug Category Introduction
      • 3.1.1 Etanercept Biosimilar
      • 3.1.2 Tocilizumab Biosimilar
      • 3.1.3 Sarilumab
      • 3.1.4 Adalimumab Biosimilar
      • 3.1.5 Others
    • 3.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market by Category
      • 3.2.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume by Category (2016-2021)
      • 3.2.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Value by Category (2016-2021)
      • 3.2.3 Global Polyarticular Juvenile Idiopathic Arthritis Drug Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Polyarticular Juvenile Idiopathic Arthritis Drug Market Status by End User/Segment

    • 4.1 Polyarticular Juvenile Idiopathic Arthritis Drug Segment by End User/Segment
      • 4.1.1 Hospital
      • 4.1.2 Clinic
      • 4.1.3 Others
    • 4.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market by End User/Segment
      • 4.2.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Polyarticular Juvenile Idiopathic Arthritis Drug Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Status by Region

    • 5.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market by Region
      • 5.1.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume by Region
      • 5.1.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Value by Region
    • 5.2 North America Polyarticular Juvenile Idiopathic Arthritis Drug Market Status
    • 5.3 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Market Status
    • 5.4 Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Market Status
    • 5.5 Central & South America Polyarticular Juvenile Idiopathic Arthritis Drug Market Status
    • 5.6 Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Market Status

    6 North America Polyarticular Juvenile Idiopathic Arthritis Drug Market Status

    • 6.1 North America Polyarticular Juvenile Idiopathic Arthritis Drug Market by Country
      • 6.1.1 North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume by Country (2016-2021)
      • 6.1.2 North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Market Status

    • 7.1 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Market by Country
      • 7.1.1 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Market Status

    • 8.1 Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Market by Country
      • 8.1.1 Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Polyarticular Juvenile Idiopathic Arthritis Drug Market Status

    • 9.1 Central & South America Polyarticular Juvenile Idiopathic Arthritis Drug Market by Country
      • 9.1.1 Central & South America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Market Status

    • 10.1 Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Market by Country
      • 10.1.1 Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Polyarticular Juvenile Idiopathic Arthritis Drug Manufacturing Cost Analysis
    • 11.5 Polyarticular Juvenile Idiopathic Arthritis Drug Sales Channel and Distributors Analysis
      • 11.5.1 Polyarticular Juvenile Idiopathic Arthritis Drug Sales Channel
      • 11.5.2 Polyarticular Juvenile Idiopathic Arthritis Drug Distributors
    • 11.6 Polyarticular Juvenile Idiopathic Arthritis Drug Downstream Major Buyers

    12 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Forecast by Category and by End User/Segment

    • 12.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Forecast by Category
      • 12.2.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume Forecast by Category
      • 12.2.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Value Forecast by Category
      • 12.2.3 Global Polyarticular Juvenile Idiopathic Arthritis Drug Price Forecast by Category
    • 12.3 Global Polyarticular Juvenile Idiopathic Arthritis Drug Forecast by End User/Segment
      • 12.3.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Value Forecast by End User/Segment
      • 12.3.3 Global Polyarticular Juvenile Idiopathic Arthritis Drug Price Forecast by End User/Segment

    13 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Forecast by Region/Country

    • 13.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Forecast by Region (2022-2027)
      • 13.1.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 UCB SA
      • 14.1.1 Company Information
      • 14.1.2 Polyarticular Juvenile Idiopathic Arthritis Drug Product Introduction
      • 14.1.3 UCB SA Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Sandoz International GmbH
      • 14.2.1 Company Information
      • 14.2.2 Polyarticular Juvenile Idiopathic Arthritis Drug Product Introduction
      • 14.2.3 Sandoz International GmbH Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Regeneron Pharmaceuticals Inc
      • 14.3.1 Company Information
      • 14.3.2 Polyarticular Juvenile Idiopathic Arthritis Drug Product Introduction
      • 14.3.3 Regeneron Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Panacea Biotec Ltd
      • 14.4.1 Company Information
      • 14.4.2 Polyarticular Juvenile Idiopathic Arthritis Drug Product Introduction
      • 14.4.3 Panacea Biotec Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Oncodesign SA
      • 14.5.1 Company Information
      • 14.5.2 Polyarticular Juvenile Idiopathic Arthritis Drug Product Introduction
      • 14.5.3 Oncodesign SA Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Oncobiologics Inc
      • 14.6.1 Company Information
      • 14.6.2 Polyarticular Juvenile Idiopathic Arthritis Drug Product Introduction
      • 14.6.3 Oncobiologics Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Mycenax Biotech Inc
      • 14.7.1 Company Information
      • 14.7.2 Polyarticular Juvenile Idiopathic Arthritis Drug Product Introduction
      • 14.7.3 Mycenax Biotech Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Momenta Pharmaceuticals Inc
      • 14.8.1 Company Information
      • 14.8.2 Polyarticular Juvenile Idiopathic Arthritis Drug Product Introduction
      • 14.8.3 Momenta Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Livzon Pharmaceutical Group Inc
      • 14.9.1 Company Information
      • 14.9.2 Polyarticular Juvenile Idiopathic Arthritis Drug Product Introduction
      • 14.9.3 Livzon Pharmaceutical Group Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Coherus BioSciences Inc
      • 14.10.1 Company Information
      • 14.10.2 Polyarticular Juvenile Idiopathic Arthritis Drug Product Introduction
      • 14.10.3 Coherus BioSciences Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Biocon Ltd

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Polyarticular Juvenile Idiopathic Arthritis Drug market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Polyarticular Juvenile Idiopathic Arthritis Drug market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Etanercept Biosimilar
      Tocilizumab Biosimilar
      Sarilumab
      Adalimumab Biosimilar
      Others

      Segmented by End User/Segment
      Hospital
      Clinic
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      UCB SA
      Sandoz International GmbH
      Regeneron Pharmaceuticals Inc
      Panacea Biotec Ltd
      Oncodesign SA
      Oncobiologics Inc
      Mycenax Biotech Inc
      Momenta Pharmaceuticals Inc
      Livzon Pharmaceutical Group Inc
      Coherus BioSciences Inc
      Biocon Ltd
      Buy now